| Analysis | Metabolite Name | Measured Value | Units | Group |
|---|---|---|---|---|
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.2352 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.2417 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.3378 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.3611 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.3949 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.4709 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.4934 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5027 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5111 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5413 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5448 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5538 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5544 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5573 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5690 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5862 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5923 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.5996 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6244 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6619 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6640 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6702 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6717 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.6769 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7060 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7165 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7198 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7219 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7271 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7308 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7355 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7384 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7394 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7458 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7552 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7591 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7611 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7767 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7790 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7807 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7836 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7955 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.7999 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8109 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8262 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8305 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8418 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8553 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8622 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8670 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8714 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8738 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8776 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8921 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.8986 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9027 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9192 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9234 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9400 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9407 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9432 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9549 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9578 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 0.9644 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0000 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0145 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0370 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0535 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0552 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0591 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0593 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0655 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0681 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0701 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0785 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0822 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0846 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.0929 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1153 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1213 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1362 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1437 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1546 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1751 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.1867 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2333 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2476 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2754 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2800 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.2871 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.3008 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.3309 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.3881 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.4056 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.4523 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.4722 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.4889 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.5300 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.5784 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.5869 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.6059 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.6342 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.6652 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.6671 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.7291 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.7486 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.7677 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.7808 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.7829 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.8152 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.8455 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.8469 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.8611 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.8889 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.9367 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 1.9952 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.0355 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.0414 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.0932 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.1061 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.2334 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.2701 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.3016 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.3950 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.5085 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.6001 | Peak area | Lean |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.8125 | Peak area | Obese neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 2.8270 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 3.1005 | Peak area | Obese non neuropathy |
| Reversed phase POSITIVE ION MODE | docosahexaenoate (DHA; 22:6n3) | 4.2185 | Peak area | Lean |
- UCSD Metabolomics Workbench, a resource sponsored by the Common Fund of the National Institutes of Health
|